Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD, University College London Hospitals, London, UK, comments on the optimal sequencing of CAR T-cell therapy and other immunotherapies, namely bispecific antibodies (bsAb), in patients with multiple myeloma (MM). BCMA-targeted CAR-T should be administered as early as possible in the treatment pathway due to a lower associated risk of T-cell exhaustion and infection than continuous bsAb administration. If relapse occurs, Dr Popat suggests the preferential use of a GPRC5D-targeting bsAb such as talquetamab. Additionally, the antibody-drug conjugate belantamab mafodotin can be an effective treatment option both prior to and following CAR-T due to its distinct mechanism of action. This interview took place at the EBMT-EHA 6th European CAR T-cell Meeting in Valencia, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.